CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy

Daisuke Ennishi, K. Takeuchi, M. Yokoyama, H. Asai, Y. Mishima, Y. Terui, S. Takahashi, H. Komatsu, K. Ikeda, M. Yamaguchi, R. Suzuki, M. Tanimoto, K. Hatake

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: Several biomarkers indicating poor prognosis have been reassessed in patients receiving rituximab combination chemotherapy for diffuse large B-cell lymphoma (DLBCL). However, few studies have investigated outcome in relation to a combination of these biomarkers. In addition, no large-scale studies have reassessed the outcome of patients with CD5-positive DLBCL treated with rituximab. Patients and methods: We conducted a retrospective study and investigated the predictive value of three biomarkers - BCL2, germinal center (GC) phenotype and CD5 - in 121 DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Results: CD5-positive patients showed significantly poorer event-free survival (EFS) and overall survival (OS) than CD5-negative patients (2-year EFS, 18% versus 73%, P <0.001; 2-year OS, 45% versus 91%, P = 0.001). However, no significant difference in outcome according to BCL2 or GC phenotype was observed. Multivariate analysis revealed that CD5 expression was a significant prognostic factor for EFS [hazard ratio 14.2, 95% confidence interval (CI) 4.7-43.2] and OS (hazard ratio 20.3, 95% CI 3.6-114.4). Conclusions: CD5 expression was the only significant prognostic factor among the biomarkers examined in this study. Further studies with larger numbers are warranted to confirm the prognostic significance of CD5 expression for patients with DLBCL receiving rituximab-containing chemotherapy.

Original languageEnglish
Pages (from-to)1921-1926
Number of pages6
JournalAnnals of Oncology
Volume19
Issue number11
DOIs
Publication statusPublished - 2008

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Biomarkers
Disease-Free Survival
Germinal Center
Therapeutics
Survival
Confidence Intervals
Phenotype
Vincristine
Prednisone
Rituximab
Combination Drug Therapy
Doxorubicin
Cyclophosphamide
Multivariate Analysis
Retrospective Studies
Drug Therapy

Keywords

  • Biomarker
  • CD5
  • Diffuse large B-cell lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. / Ennishi, Daisuke; Takeuchi, K.; Yokoyama, M.; Asai, H.; Mishima, Y.; Terui, Y.; Takahashi, S.; Komatsu, H.; Ikeda, K.; Yamaguchi, M.; Suzuki, R.; Tanimoto, M.; Hatake, K.

In: Annals of Oncology, Vol. 19, No. 11, 2008, p. 1921-1926.

Research output: Contribution to journalArticle

Ennishi, D, Takeuchi, K, Yokoyama, M, Asai, H, Mishima, Y, Terui, Y, Takahashi, S, Komatsu, H, Ikeda, K, Yamaguchi, M, Suzuki, R, Tanimoto, M & Hatake, K 2008, 'CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy', Annals of Oncology, vol. 19, no. 11, pp. 1921-1926. https://doi.org/10.1093/annonc/mdn392
Ennishi, Daisuke ; Takeuchi, K. ; Yokoyama, M. ; Asai, H. ; Mishima, Y. ; Terui, Y. ; Takahashi, S. ; Komatsu, H. ; Ikeda, K. ; Yamaguchi, M. ; Suzuki, R. ; Tanimoto, M. ; Hatake, K. / CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. In: Annals of Oncology. 2008 ; Vol. 19, No. 11. pp. 1921-1926.
@article{2955c57397b540ed994370d1973e029e,
title = "CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy",
abstract = "Background: Several biomarkers indicating poor prognosis have been reassessed in patients receiving rituximab combination chemotherapy for diffuse large B-cell lymphoma (DLBCL). However, few studies have investigated outcome in relation to a combination of these biomarkers. In addition, no large-scale studies have reassessed the outcome of patients with CD5-positive DLBCL treated with rituximab. Patients and methods: We conducted a retrospective study and investigated the predictive value of three biomarkers - BCL2, germinal center (GC) phenotype and CD5 - in 121 DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Results: CD5-positive patients showed significantly poorer event-free survival (EFS) and overall survival (OS) than CD5-negative patients (2-year EFS, 18{\%} versus 73{\%}, P <0.001; 2-year OS, 45{\%} versus 91{\%}, P = 0.001). However, no significant difference in outcome according to BCL2 or GC phenotype was observed. Multivariate analysis revealed that CD5 expression was a significant prognostic factor for EFS [hazard ratio 14.2, 95{\%} confidence interval (CI) 4.7-43.2] and OS (hazard ratio 20.3, 95{\%} CI 3.6-114.4). Conclusions: CD5 expression was the only significant prognostic factor among the biomarkers examined in this study. Further studies with larger numbers are warranted to confirm the prognostic significance of CD5 expression for patients with DLBCL receiving rituximab-containing chemotherapy.",
keywords = "Biomarker, CD5, Diffuse large B-cell lymphoma, Rituximab",
author = "Daisuke Ennishi and K. Takeuchi and M. Yokoyama and H. Asai and Y. Mishima and Y. Terui and S. Takahashi and H. Komatsu and K. Ikeda and M. Yamaguchi and R. Suzuki and M. Tanimoto and K. Hatake",
year = "2008",
doi = "10.1093/annonc/mdn392",
language = "English",
volume = "19",
pages = "1921--1926",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy

AU - Ennishi, Daisuke

AU - Takeuchi, K.

AU - Yokoyama, M.

AU - Asai, H.

AU - Mishima, Y.

AU - Terui, Y.

AU - Takahashi, S.

AU - Komatsu, H.

AU - Ikeda, K.

AU - Yamaguchi, M.

AU - Suzuki, R.

AU - Tanimoto, M.

AU - Hatake, K.

PY - 2008

Y1 - 2008

N2 - Background: Several biomarkers indicating poor prognosis have been reassessed in patients receiving rituximab combination chemotherapy for diffuse large B-cell lymphoma (DLBCL). However, few studies have investigated outcome in relation to a combination of these biomarkers. In addition, no large-scale studies have reassessed the outcome of patients with CD5-positive DLBCL treated with rituximab. Patients and methods: We conducted a retrospective study and investigated the predictive value of three biomarkers - BCL2, germinal center (GC) phenotype and CD5 - in 121 DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Results: CD5-positive patients showed significantly poorer event-free survival (EFS) and overall survival (OS) than CD5-negative patients (2-year EFS, 18% versus 73%, P <0.001; 2-year OS, 45% versus 91%, P = 0.001). However, no significant difference in outcome according to BCL2 or GC phenotype was observed. Multivariate analysis revealed that CD5 expression was a significant prognostic factor for EFS [hazard ratio 14.2, 95% confidence interval (CI) 4.7-43.2] and OS (hazard ratio 20.3, 95% CI 3.6-114.4). Conclusions: CD5 expression was the only significant prognostic factor among the biomarkers examined in this study. Further studies with larger numbers are warranted to confirm the prognostic significance of CD5 expression for patients with DLBCL receiving rituximab-containing chemotherapy.

AB - Background: Several biomarkers indicating poor prognosis have been reassessed in patients receiving rituximab combination chemotherapy for diffuse large B-cell lymphoma (DLBCL). However, few studies have investigated outcome in relation to a combination of these biomarkers. In addition, no large-scale studies have reassessed the outcome of patients with CD5-positive DLBCL treated with rituximab. Patients and methods: We conducted a retrospective study and investigated the predictive value of three biomarkers - BCL2, germinal center (GC) phenotype and CD5 - in 121 DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Results: CD5-positive patients showed significantly poorer event-free survival (EFS) and overall survival (OS) than CD5-negative patients (2-year EFS, 18% versus 73%, P <0.001; 2-year OS, 45% versus 91%, P = 0.001). However, no significant difference in outcome according to BCL2 or GC phenotype was observed. Multivariate analysis revealed that CD5 expression was a significant prognostic factor for EFS [hazard ratio 14.2, 95% confidence interval (CI) 4.7-43.2] and OS (hazard ratio 20.3, 95% CI 3.6-114.4). Conclusions: CD5 expression was the only significant prognostic factor among the biomarkers examined in this study. Further studies with larger numbers are warranted to confirm the prognostic significance of CD5 expression for patients with DLBCL receiving rituximab-containing chemotherapy.

KW - Biomarker

KW - CD5

KW - Diffuse large B-cell lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=54949091570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949091570&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdn392

DO - 10.1093/annonc/mdn392

M3 - Article

C2 - 18573805

AN - SCOPUS:54949091570

VL - 19

SP - 1921

EP - 1926

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -